NR1H4 and metabolic dysfunction-associated steatohepatitis: Currently, targeting nuclear receptors (FXR agonists, PPAR agonists, etc.)or modulating peptide hormones (growth hormone-releasing hormone, fibroblast growth factors, etc.)to ameliorate NASH has gained much attention, and drugs that do so are being developed [8].